Contribution of the GSTP1 c.313A>G variant to hearing loss risk in patients exposed to platin chemotherapy during childhood.

P H P LibermanMaria Valéria Schmidt Goffi GomezC SchultzP L JacobC A A de PaulaE L SartoratoG T TorrezanE N FerreiraD M Carraro

Published in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2018)

The GSTP1 c.313A>G variant may increase the risk of low-frequency HL in pediatric oncology patients treated with cisplatin or carboplatin chemotherapy.

Keyphrases

end stage renal disease
newly diagnosed
chronic kidney disease
ejection fraction
locally advanced
hearing loss
palliative care
peritoneal dialysis
squamous cell carcinoma
randomized controlled trial
young adults
radiation therapy
study protocol
open label
chemotherapy induced